Höre Beyond Biotech - the podcast from Labiotech

Are TCR-NK treatments the next big thing in cell therapies for cancer patients? As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norwegian biotech is taking a slightly different track. This week, we sit down with Namir Hassan, CEO of Zelluna, a company with a mission to eliminate solid cancers by pioneering the development of T cell receptor guided natural killer, or TCR-NK, cell therapies. 01:45                      Introducing Namir Hassan 03:37                      Working at Immunocore 04:40                      Lessons learned 06:56                      Joining Zelluna as CSO 08:44                      Becoming Zelluna CEO 10:20                      Taking a biotech company public 12:54                      TCR-T and TCR-NK therapies 15:30                      Targets for TCR-NK therapies 16:38                      Comparing TCR-NK to alternatives 20:16                      Early success 21:58                      An off-the-shelf-solution for cancer patients 24:16                      Manufacturing and scaling 25:13                      Partnering with top pharma, accelerating innovation 27:05                      Milestones ahead for Zelluna 28:52                      The landscape of TCR therapies in oncology 31:38                      A final word Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! [https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast]  Stay updated by subscribing to our newsletter [https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast] To dive deeper into the topic:  * Future of cancer treatment: what will therapy look like in 2034? [https://www.labiotech.eu/in-depth/what-is-the-future-of-cancer-treatment/] * Trends in cancer therapeutics to look forward to in 2025 [https://www.labiotech.eu/in-depth/oncology-trends-2025/] * Oncology R&D trends and breakthrough innovations [https://www.inpart.io/insights/oncology-rd-trends-and-breakthrough-innovations?utm_campaign=Oncology_RD_trends_report&utm_medium=audio&utm_source=labiotech.eu]

AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging? David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovative biotech that is leveraging the power of AI to accelerate drug discovery and development from its Paris, Boston, and Montreal bases. In this episode he explains how WhiteLab uses AI technologies to identify targets and engineer vectors, but also offers a wider view of how and where AI is impacting the biotech industry generally. 01:04               Introducing David del Bourgo 04:06               The WhiteLab Genomics mission 10:54               AI in biotech: what’s working now 14:07               AI in biotech: emerging applications 15:58               Regulating AI in biotech and in general 17:21               Acceleration and cost savings thanks to AI 19:09               AI’s impact on accuracy and precision 21:07               The trade-off with AI in biotech 22:38               Why top pharma companies aren’t building their own AI tools 24:43               AI and biomanufacturing 26:58               AI in biotech and pharma operations 28:40               The next impacts of AI in biotech 30:38               Accelerating regulatory review with AI 32:24               Emerging AI techniques in biotech 33:59               The pace of AI innovation 35:21               The next challenge for AI in biotech 36:10               A word for the AI skeptics  Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! [https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast]  Stay updated by subscribing to our newsletter [https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast] To dive deeper into the topic:  * 12 AI drug discovery companies you should know about [https://www.labiotech.eu/best-biotech/ai-drug-discovery-companies/] * The AI boom in cancer: Game-changer or just hype? [https://www.labiotech.eu/in-depth/ai-oncology/] * Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration [https://www.labiotech.eu/trends-news/ai-biotech-bubble/]

From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy. Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to launch MoonLake in 2021 and quickly helped move their lead candidate to the clinic. Now, on the verge of Phase III trials, he joins 'Beyond Biotech' to talk nanobodies, innovation, serendipitous science, and the power that comes from never stopping to dream. 01:04               Meet Kristian Reich 05:26               Excited by the science of nanobodies 07:13               MoonLake’s mission 13:12               Milestones at MoonLake 15:24               Introduction to nanobodies 17:55               Serendipitous science 19:46               How nanobodies work 23:18               Global prevelance of immune conditions 24:31               The impact on patients 27:09               Nanobodies in the clinic 31:19               Manufacturing challenges, regulatory challenges 34:04               Working with top pharma 35:55               The future of nanobodies 37:42               The future of MoonLake 39:10               Don’t stop dreaming Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! [https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast]  Stay updated by subscribing to our newsletter [https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast]

Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs? Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his team have developed the Cell Shuttle, an advanced cell manufacturing technology that is already demonstrating the potential to 10x cell yields while halving costs for pharmaceuticals companies and innovators. Is this the future for smart cell manufacturing? 0:52     A starting point in aeronautical engineering 2:43     First steps into biotech 5:25     Co-founding Cellares 6:30     The problem that Cellares addresses 11:02   Best practice bio manufacturing 17:14   Differentiation in automation 18:15   What does success look like for Cellares 19:38   Smart factories 21:58   Inside the Cellares smart factory 26:34   Manufacturing CAR-T and stem cell therapies 27:54   Mass production vs personalized medicine 31:39   Global ambitions and regional regulators 35:07   Positioning Cellares in the market Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! [https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast]  Stay updated by subscribing to our newsletter [https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast]

Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike. Brian Culley is CEO of Lineage Cell Therapeutics and his company is now in the clinic with a stem cell therapy for spinal cord injuries. Learn why stem cells could be promising for these devastating injuries and how Brian and his team plan to overcome the challenges of manufacturing at scale and succeeding in a highly regulated space. 00:57              Meet Brian Culley 02:15               Lineage Cell Therapeutics and its mission 04:56              Spinal cord injuries 06:40              Costs beyond the Individual 08:15               Current treatment options 10:48               The place for stem cell therapies 12:57                Lineage in the clinic 16:27                The DOSED program 18:37                The advantages of DOSED 20:29               Timelines for results 21:35               Scaling manufacturing 24:28               Partnering with pharma on stem cell therapies 26:38               Other applications for stem cell therapies 28:49               Mainstreaming stem cell therapies 30:52               Challenges ahead 32:43               The future for Lineage Cell Therapeutics Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! [https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast]  Stay updated by subscribing to our newsletter [https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast]